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ABSTRACT
Antibiotic use continues to be the most important
risk factor for the development of Clostridium
difficile infection (CDI) through disruption of the
indigenous microbiota of the colon. This factor,
together with environmental contamination,
makes hospital and other healthcare facilities
the perfect breeding ground for the infection.
Several groups of patients are exposed to the
hospital environment and, at the same time,
affected by conditions that can make CDI more
prevalent, more severe or make it present a
different clinical picture. The list of such
conditions appears too extensive to be reviewed
in a single article. Nevertheless, several groups,
including the critically ill, oncological patients,
solid organ and hematopoietic transplant
recipients, patients with inflammatory bowel
disease, patients with kidney disease and
pregnant women, have generated more
attention and have been studied in more detail.
On the other hand, pediatric patients constitute a
controversial group because the large number of
asymptomatic carriers makes interpretation of
clinical findings and diagnostic tests difficult, as is
the development of an appropriate approach to
treatment. We present an in-depth discussion of
CDI in these high-risk populations and we also
review the issue of CDI in pediatric patients.
Keywords: Children; Clostridium difficile;
Inflammatory bowel disease; Intensive care
units; Kidney diseases; Neoplasms; Pregnancy;
Transplantation
INTRODUCTION
Clostridium difficile infection (CDI) is a health
problem of great magnitude due to its
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increasing incidence and its elevated morbidity
and mortality [1]. It is caused by an anaerobic
bacterium capable of proliferating in the
intestine and, under certain circumstances,
damaging the mucosa by producing toxins.
Antibiotic use continues to be the most
important risk factor for the development of
C. difficile infection (CDI) through disruption of
the indigenous microflora of the colon [2].
Environmental contamination constitutes
another relevant risk factor determining
healthcare facilities to became the perfect
breeding ground for the infection [3].
The main manifestations of this infection are
diarrhea and abdominal pain that can also be
present in patients with other infections
(Salmonella, E. coli, norovirus, etc.), suffering
from inflammatory diseases or receiving certain
drugs [4].
Certain populations have generated
increased attention due to a higher incidence
of this disease, to suffering from a more severe
disease or to presenting greater difficulty in the
interpretation of diagnostic tests because of the
existence of other common causes of diarrhea.
The aim of this review is to deepen the
knowledge of the peculiarities of this infection in
relevant populations such as critically ill patients,
oncological patients, hematopoietic stem cell and
solid organ transplant recipients, patients with
inflammatory bowel disease, patients with renal
diseases, pregnant women and children.
To perform this review, original articles,
meta-analysis and reviews have been
considered. We searched the PubMed database
for English language references published from
1980 to 2016 crossing the terms: ‘‘Clostridium
difficile’’ or ‘‘Pseudomembarnous colitis’’ with
‘‘Intensive Care, Units’’, ‘‘Critically Illness’’,
‘‘Hematologic Neoplasms’’, ‘‘Transplantation’’,
‘‘Inflammatory Bowel Disease’’, ‘‘Kidney Failure,
Chronic renal failure’’, ‘‘Pregnancy’’, ‘‘Child’’
and ‘‘Children’’.
This article is based on previously conducted
studies and does not involve any new studies of
human or animal subjects performed by any of
the authors.
CRITICALLY ILL PATIENTS WITH CDI
CDI in patients admitted to an intensive care
unit (ICU) represents an important problem due
to its high prevalence and high rate of
complications [5]. It is estimated that around
11% of episodes of diarrhea in ICU patients are
due to CDI. However, CDI incidence may differ
between countries, as highlighted in a recent
multicenter study from Spain, which showed a
low rate of CDI in ICU patients [6]. This
infection may determine a higher length of
ICU and hospital stay, and a higher overall
mortality rate that can reach 30% [5]. One study
revealed that patients with CDI in the ICU also
had a higher risk of complications such as shock
and need for surgery [7]. Bouza et al. observed
that patients admitted to the ICU due to CDI
presented a much more complicated evolution
than CDI episodes developed during an ICU
stay [8]. Factors associated with a complicated
course were a high Simplified Acute Physiology
Score (SAPS II), high Sequential Organ Failure
Assessment (SOFA) score, and
hypoalbuminemia at the onset of CDI [8].
This group may present multiple CDI risk
factors which include: comorbidities (such as
renal failure and diabetes mellitus)
immunosuppression, enteral nutrition,
broad-spectrum antibiotics, proton-pump
inhibitor administration and steroid treatment
[5]. Although classical studies have shown C.
difficile colonization as a protective factor for
development of CDI, a recent study has found
254 Infect Dis Ther (2016) 5:253–269
that C. difficile colonization before ICU
admission constitutes an independent risk
factor for CDI during ICU stay [9]. Further
studies are necessary to confirm these findings
and to establish its potential implications.
Severe colitis may present with fever,
abdominal pain and distension. In fact, up to
20% of patients with CDI in the ICU can
present ileus without diarrhea which
complicates the diagnosis of this infection
[10, 11]. Analytical findings, such as
leukocytosis, bandemia and increased serum
lactic dehydrogenase levels, may lead to
suspicion of CDI in these patients [12]. It is
remarkable that an elevated proportion of these
patients (up to 25%) are diagnosed by the
presence of pseudomembranes detected
through endoscopy or other medical imaging
techniques [5]. Furthermore, critically ill
patients have a higher risk of CDI recurrence,
especially if other risk factors, such as Chronic
Obstructive Pulmonary Disease, prior CDI
during the previous year, prolonged ICU stay
and ICU acquired infection, are present [13].
As in other patient groups, treatment of CDI
in the critically ill depends on the severity of the
infection [11, 14]. If oral medication is not
suitable, administration of intracolonic
vancomycin should be considered [11]. In a
small study that included patients with CDI,
Rokas et al. observed higher survival using
combination therapy with oral vancomycin
and intravenous metronidazole in comparison
to oral vancomycin [15]. Nevertheless, the study
was uncontrolled and causes of mortality were
not addressed. Pivotal clinical trials of
fidaxomicin excluded critically ill patients;
however, some reports of limited experience
with this drug have recently been published,
including the use of crushed tablets
administered by nasogastric tube [16–18]. Fecal
microbiota transplantation (FMT) can also be
considered in patients who do not respond to
antibiotics against C. difficile [19]. Surgical
consultation should be carried out in patients
with extensive colitis and unfavorable
evolution. Up to 20% of patients with CDI in
the ICU may require colectomy or other surgical
procedures [20], such as diverting loop
ileostomy and colonic lavage [21, 22]. Early
surgery can reduce mortality and may be more
beneficial in patients aged 65 years or more, the
immunocompetent, and those with leukocytosis
or a moderate serum lactate increase [23].
Finally, it should be pointed out that
antibiotic stewardship programs and specific
infection control measures can reduce the
incidence and severity of CDI in these patients
[5].
CDI INFECTION IN ONCOLOGICAL
PATIENTS
Oncological patients suffer high rates of CDI
due to the frequent presence of risk factors such
as recurrent hospitalizations,
immunosuppression, antibiotic use (either for
prophylactic or therapeutic purposes),
chemotherapy and the use of enteral and
parenteral nutrition [24]. Despite the
suggestion that patients with gastrointestinal
tumors have a lesser predisposition to CDI and
that patients with breast cancer are more prone
to this infection, up to now, no clear
relationship between the type of cancer and
the risk of CDI has been described [25].
Similarly, some chemotherapy drugs, such as
platinum-based agents, taxanes and
DNA-topoisomerase inhibitors, have been
reported to be more related to CDI than others
[26]. However, other studies did not find that
any specific chemotherapy drug was especially
related to a higher risk of CDI [25]. The
pathogenesis of chemotherapy-related CDI is
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not well understood. One suggested mechanism
is chemotherapy-mediated fecal microbiota
disruption, which creates an environment that
is appropriate for C. difficile growth [26]. Other
possible mechanisms are inflammatory changes
in the intestinal mucosa, a decrease in C. difficile
toxin deterioration and cancer-related
immunological changes that could predispose
patients to CDI [27–29].
In these patients, diarrhea is the most
common clinical manifestation of CDI,
together with fever and abdominal pain, as in
other groups [25]. Moreover, CDI can require a
wide-ranging differential diagnosis because
either chemotherapy drugs or other intestinal
pathogens could also cause diarrhea.
Neutropenia is common in oncological
patients; therefore, it is very important to
consider that white cell counts might not be
appropriate for evaluating the severity of CDI in
this group [26].
Treatment of CDI in oncological patients is
similar to other groups, but could be complicated
by general deterioration, the presence of
mucositis and chemotherapy-related nausea.
The recurrent CDI rate in oncological patients is
similar to the general population [30].
Nevertheless, the impact of CDI can be
significant since it may result in the delay or
dose reduction of chemotherapy and/or
radiotherapy in some patients [24, 25].
Due to the complex physiopathology of CDI
in oncological patients, broader prospective
studies are needed to explore the risk factors
and behavior of this infection in this group.
CDI INFECTION
IN HEMATOLOGICAL PATIENTS
The annual incidence of CDI in these patients
fluctuates between 5% and 20%, which is
consistent with the especial susceptibility to
infection of hematopoietic stem cell transplant
(HSCT) recipients [31]. Higher rates of CDI in
allogeneic HSCT recipients may be due to a
higher concurrence of the main risk factors for
CDI in this population: prolonged
hospitalization, gastrointestinal mucosa
damage due to chemotherapy drugs,
antibiotics, radiotherapy and gastrointestinal
graft-versus-host disease (GvHD) [31, 32].
However, the relationship between CDI and
GvHD is complex because CDI may increase the
risk of GvHD during the first year after
infection, which suggests that microbial
antigenicity and/or the patient’s response to
the infection may be involved in its
pathogenesis [26, 31].
An increased proportion of CDI episodes
appear within the first weeks after transplant
[26]. This fact, together with the use of
conditioning chemotherapeutic regimens,
suggests that C. difficile colonization prior to
transplant has a relevant role in a large number of
these patients [31]. The frequency of
pseudomembranes is low in hematological
patients, which may be related to their
limited inflammatory response due to
immunosuppression, and the possible detection
of C. difficile carriage in those suffering from
other causes of diarrhea [33, 34]. Distinguishing
between CDI and other causes of diarrhea, such
as conditioning chemotherapeutic drugs, GvHD
and cytomegalovirus infection, presents an
important diagnostic difficulty in these patients
[31, 32]. It should be considered that a positiveC.
difficile test, especially the polymerase chain
reaction (PCR), does not always confirm that
this pathogen is the cause of the diarrhea and
that it may simply represent colonization in a
patient presenting with diarrhea due to another
cause [35].
Recurrent CDI appears in approximately
20% of these patients, similar to the general
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population [31]. In one study of CDI in
allogeneic HSCT recipients, Mani et al. found
exposure to antibiotics to be the unique risk
factor for recurrence [32]. This study did not
reveal any relationship between GvHD and
recurrence as was observed in a previous study
[31].
Treatment of CDI in hematological patients is
similar to other groups and is based on the
severity of infection. Parmar et al. did not observe
any differences in response to vancomycin or
metronidazole [36]. Nevertheless, considering
the frequent presence of metallic taste,
mucositis and nausea in patients treated with
metronidazole, vancomycin is preferred in
oncohematological patients [26]. Finally, due to
the possibility of sepsis in neutropenic and other
immunocompromised patients, probiotics
should be used with caution [26].
HSCT recipients are especially vulnerable to
infection and are at higher risk of CDI. Further
investigation is required to optimize diagnostic
algorithms and treatment options in these
patients.
CDI IN THE SOLID ORGAN
TRANSPLANT RECIPIENT
CDI is a relevant problem in solid organ
transplant (SOT) [37]. It is estimated that the
risk of CDI in this group is up to five times
higher than in other patients, and is related to
the frequent exposure to common risk factors
for CDI, such as hospital environment,
antibiotic and immunosuppressive therapies
[37, 38].
Paudel et al. estimated a CDI prevalence of
7.4% in SOT patients [38]. This meta-analysis
demonstrated that liver and lung transplant
patients, as well as multiorgan recipients,
tended to have a higher rate of CDI compared
to kidney transplant recipients. Most cases of
CDI in these patients are diagnosed during the
early postoperative period and are due to greater
exposure to the above-mentioned risk factors
during this time [38]. CDI in SOT patients is also
associated with higher mortality, more hospital
readmissions and admissions to intensive care
units (ICU), longer in-hospital stay, higher costs
and worse transplant outcomes [37].
This group presents diagnostic difficulties
because diarrhea is a very common
complication in SOT patients, and can be
caused by infectious and non-infectious
conditions. Immunosuppressive drugs
themselves are a frequent cause of
non-infectious diarrhea, with C. difficile,
cytomegalovirus and norovirus being the most
frequent infectious causes [39].
Knowledge about complications and
mortality in this group is limited. Some studies
maintain that SOT recipients with CDI have
longer in-hospital stay, greater in-hospital
mortality and higher costs [40, 41]. Similarly,
CDI has been related to graft dysfunction and a
higher risk of other infections (pneumonia,
cytomegalovirus) [41]. However, complicated
CDI has only been observed in 5% of these
patients [42].
With respect to treating CDI, there are no
specific recommendations for this group of
patients. Due to their frequent exposure to
antibiotics, it is especially important to
consider discontinuing predisposing drugs of
this type. Initial treatment in mild and
moderate cases of CDI in SOT recipients has
been based on oral metronidazole [43]. As for
other groups, oral vancomycin is the treatment
of choice in severe CDI. Due to their potential
interactions, adequate plasma level monitoring
of immunosuppressive drugs is crucial during
treatment with antibiotics, including
metronidazole [44]. It is remarkable that some
patients tend to present leukopenia after
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transplant, which may mean a misclassification
of CDI severity due to the inability to develop
leukocytosis [45].
Fidaxomicin is a novel macrocyclic
antibiotic that has demonstrated a similar
clinical response but with a lower CDI
recurrence rate than oral vancomycin [46, 47].
One study revealed no differences in cure rates
of CDI for fidaxomicin and conventional
treatment in SOT and hematopoietic stem cell
transplant patients, but lower selection of
vancomycin-resistant enterococci among those
treated with this novel agent [48]. This study
also reported that patients treated with
fidaxomicin did not demonstrate any
significant variations between plasma
concentrations of immunosuppressive drugs.
Surgical consultation should be carried out
in the cases of patients who do not progress
favorably because the incidence of fulminant
colitis may be higher in SOT recipients [43]. In
fact, Boutros et al. showed good outcomes
when colectomy was performed early in
patients with complicated CDI [39, 49]. In
patients with multiple recurrences, treatment
can be based on oral vancomycin with a
pulse-dosing or prolonged tapering schedule,
with similar results [39]. There is little
experience with fecal bacteriotherapy in SOT
recipients. Fecal microbiota transplantation
has been employed in some cases with good
outcomes and no relevant side effects [50].
However, these patients are not usually
considered candidates for these therapies due
to their theoretical (but unproved) potential
for infection [43].
Despite the special clinical features of SOT
recipients, the risk of recurrent CDI is similar to
other patient groups (8% and 20%) [38, 39].
Comorbidity, immunosuppression, long
hospital admission and frequent antibiotic use
are common risk factors associated to recurrent
CDI in SOT recipients [51, 52]. Screening for
hypogammaglobulinemia is advisable in CDI as
this is a predisposing and treatable factor [53].
In summary, CDI is a relevant problem in
SOT recipients and with an increasing
incidence. This infection increases mortality
and graft loss rates in these patients. Due to
the above, special efforts are considered
essential to adequately prevent, diagnose and
treat CDI in SOT patients.
CDI INFECTION IN PATIENTS
WITH INFLAMMATORY BOWEL
DISEASE
CDI is diagnosed more frequently in patients
with inflammatory bowel disease (IBD) than in
the general population [54, 55], and represents
an important burden on patients with IBD
because of the greater healthcare costs and
increased need for surgical treatment [56].
Detection of this infection could be more
difficult in these patients, because symptoms,
such as abdominal pain and diarrhea, could be
due to an exacerbation of IBD or to other
infectious causes such as cytomegalovirus colitis
[57]. Therefore, CDI screening is crucial in
patients supposedly suffering from IBD
exacerbation.
CDI in patients with IBD tends to affect
younger patients and to be community
acquired, which is in line with the great ribotype
diversity observed in community-acquired CDI as
in many IBD patients in clinical remission
colonized by C. difficile [57, 58]. It seems that
patients with ulcerative colitis have a higher risk
of CDI than patients with Crohn’s disease, which
may be related to the more common and
extensive involvement of the colon in patients
with ulcerative colitis [59].
Patients with IBD are characterized by
receiving immunosuppressive and steroid
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treatment which, in those with a deteriorated
gastrointestinal tract barrier function, may
impair immune response to this infection
[56, 60–62]. These patients often require
hospitalization and frequently undergo
endoscopic and surgical procedures which also
increase the risk of CDI [56, 60–62]. Another
issue is that some studies did not show a clear
relationship between CDI infection with
previous exposure to antibiotics in IBD
patients compared to others [54, 55]. On the
other hand, the influence of proton pump
inhibitors (PPI) on the development of CDI in
these patients is considered uncertain. Some
authors did not find any correlation between
treatment with PPI and CDI [55], whereas a
clear relationship was demonstrated by others
[58].
Clinical manifestations of CDI in patients
with IBD vary from asymptomatic colonization
to severe forms that can be life-threatening.
Although it is generally considered that patients
with IBD have more severe forms of CDI and
higher rates of complications [54, 59], some
authors did not find this relationship [58].
According to current knowledge, it cannot be
definitely assumed that the prognosis of CDI
infection in IBD patients is worse in relation to
length of in-hospital stay, colectomy and
mortality. A retrospective study of prognostic
factors revealed that a plasmatic albumin
concentration under 3 g/dL is an independent
predictor of severe outcomes of CDI in patients
with IBD [63]. Atypical presentations of CDI are
frequent in patients with IBD (e.g., bloody
diarrhea in a young patient with no previous
history of hospital admission, ileum
involvement in those patients with previous
colectomy and ‘‘infectious’’ pouchitis in patients
with an ileo-anal reservoir). In addition,
endoscopy rarely reveals pseudomembranes
and is frequently ineffective for distinguishing
between IBD exacerbation and CDI [54, 55, 60].
It appears that IBD patients do not have a high
risk of recurrence [64].
There are no specific recommendations for
the treatment of CDI in this group. Although it
is unclear that CDI in IBD patients is more
severe, some authors suggest the initial use of
vancomycin due to the presumed high risk of
complications in them [59]. Until now, no
study has analyzed the use of fidaxomicin for
the treatment of CDI in IBD patients [65]. It
seems that FMT is not as effective in the
treatment of IBD as for the treatment of CDI
[66]. One study that analyzed the use of FMT for
the treatment of recurrent CDI in patients with
IBD demonstrated that this therapy was less
effective in clearing recurrent CDI if the patient
suffered from IBD. Furthermore, around 25% of
patients with IBD had a disease flare after FMT
[67].
There are no clear recommendations with
respect to the maintenance or modification of
IBD treatment during CDI. One multicenter
retrospective study revealed that patients
treated with immunomodulators plus active
treatment against CDI more frequently
presented in-hospital megacolon, bowel
perforation, hemodynamic shock or
respiratory failure, and the primary composite
outcome was death or colectomy within
3 months of admission [68]. However, it
should be noted that the use of
immunomodulators could be a confounding
factor due to a possible selection of patients
with worse clinical state.
In summary, due to the elevated rate of
asymptomatic carriers, the difficulties related to
clinical and endoscopic diagnosis, as well as the
possible higher risk of complications and
mortality among these patients, it is important
that physicians be on the alert for CDI and
compatible clinical findings in patients with IBD.
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CDI IN PATIENTS WITH RENAL
DISEASE
Between about 8% and 12% of the world’s
population suffer from some form of chronic
kidney disease (CKD) [69]. Since patients
diagnosed with CKD are more frequently
exposed to the hospital environment, and also
frequently receive antibiotics, a higher
incidence of CDI can be expected in this group.
Perhaps the largest investigation addressing
the incidence of CDI among patients with CKD
was the study published in 2012 by Keddis et al.
By using the large National Hospital Discharge
Surveys database, they were able to calculate the
incidence of CDI in more than 160 million
hospitalizations. They found that the incidence
of CDI in patients with CKD doubles the
incidence of CDI in the general population
and that the effect was particularly high among
patients undergoing dialysis [70].
Moreover, a recent meta-analysis confirmed
that the incidence of CDI is higher in patients
with kidney disease (RR 1.95; 95% CI 1.81–2.10).
The risk even increases in the case of end-stage
renal failure (RR 2.63; 95% CI 2.04–3.38) [71].
Gastric acid suppression or microorganism
overgrowth caused by intestinal dysmotility is
frequently observed in CKD patients; this may
also contribute to an increased risk of CDI [72].
Clinicians should be especially prudent when
prescribing antibiotics for these patients, not
only due to the known increased toxicity of
several antimicrobials in patients with renal
failure but also due to the increased risk of CDI.
Does CDI cause poorer outcomes in patients
with CKD? Pant et al. compared costs, mortality
and length of stay (LOS) in patients with
end-stage renal disease and CDI with
hospitalized patients with end-stage renal
disease without CDI. They found that CDI
increased LOS by 9 days, raised costs by
US$68,000, and doubled mortality [73]. A
recent systematic review based on 4 cohort
studies quantified that CDI increased mortality
among patients with chronic renal failure (CRF)
(RR 1.73; 95% CI 1.39–2.15), and especially in
those with end-stage renal disease (RR 2.15;
95% CI 2.07–2.23) [74]. Some authors have
drawn attention to the risk of missing CDI in
patients with CRF presenting without diarrhea
(ileus). Nevertheless, it is unknown whether
these atypical clinical presentations are more
frequent among patients with CRF [75]. There is
no evidence to suggest that hemodialysis
patients with CDI have a worse prognosis; this
is perhaps due to the fact that normally they are
continuously checked and monitored [70].
A more extensive systematic review to
evaluate the outcomes of CDI among patients
with CRF or end-stage renal disease has recently
been published. The results confirmed a higher
relative risk for severe or severe-complicated
CDI (1.51; 95% CI 1.00–2.28), for risk of
mortality (1.76; 95% CI 1.26–2.47), and for
recurrence (2.73; 95% CI 1.36–5.47) [76]. One
classic study pointed out a higher risk for
recurrent CDI [77], which was confirmed by a
previously mentioned meta-analysis [71]. In
fact, several clinical prediction tools include
renal function in their scoring system [78, 79].
Recent studies have shown a better and
quicker response to vancomycin than to
metronidazole, which is more evident in
severe forms of CDI [80]. Oral vancomycin
remains almost unabsorbed and prospective
studies have confirmed that a dosage of
125 mg four times per day is not associated
with detectable vancomycin levels in serum
[81]. Nevertheless, detectable levels of
vancomycin in patients with CDI have been
reported in those treated with high dosages
[82], which could be important in patients with
renal failure and especially those with a certain
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renal functional reserve. To answer this
question, Pettit et al. studied a group of 85
patients treated with vancomycin. They found
detectable levels of vancomycin in 68%.
However, only 17.6% had levels above 2.5 mg/
L. These levels were associated with renal
disease, the use of enemas and the presence of
gastrointestinal disease [83]. In short,
conventional doses may be safely used in
patients with CRF. In exceptional cases, when
using vancomycin enemas or in patients with
concomitant intestinal diseases, vancomycin
serum concentration determinations would be
advisable.
Since patients with renal disease were
allowed to participate in pivotal clinical trials
that compared fidaxomicin with vancomycin, a
subanalysis of patients with CKD included in
these trials provided interesting prospective
information. Response to therapy was inferior
and rates of recurrence were higher in patients
with stage 4 or 5 CRF. Those treated with
fidaxomicin presented fewer recurrences than
those treated with vancomycin (absolute risk
reduction 10% for patients in stage 2, 11.6% for
patients in stage 3 and 19.6% in patients in
stage 4) [84]. In fact, the use of fidaxomicin in
persons with CRF could be cost-effective [85].
Plasma fidaxomicin concentrations are very low
and are not affected by renal function [86].
CDI IN PREGNANT WOMEN
It is known that the acquisition of C. difficile in
neonates occurs regularly during the first few
weeks of life. Although the environment seems
to be the principal source of such colonization,
it has been shown that mothers are sometimes
carriers of C. difficile in proportions ranging
between 11% and 18% [87]. Because pregnant
women are young and healthy people, they
could be considered at very low risk for CDI.
However, in 1984, a small outbreak of
pseudomembranous colitis was reported in
women that had received antibiotic
prophylaxis for caesarean section and shared
the same ward and delivery room [88]. It could
obviously have been an isolated event. In fact, a
review of CDI cases in the obstetrical and
gynecological departments of two hospitals
reported the incidence to be as low as 0.02%.
Moreover, only a small percentage of the cases
were in the obstetric areas [89].
Nevertheless, the description of new cases of
severe-complicated CDI in post-partum again
drew attention to the possibility of a higher
susceptibility to CDI during pregnancy,
particularly in peripartum or postpartum
women [90, 91]. A survey was carried out
among North American infectious disease
specialists to better understand the frequency
of CDI in pregnancy. Around 9% of those that
responded had attended or had reports of CDI
in peripartum women during the previous
6 months. The survey also allowed
information to be collected from 55 cases.
Thirty-seven per cent of them occurred around
the time of labor, and there were cases during
all three trimesters. Forty-three developed some
complication, 10 presented recurrences and 5
toxic megacolon (3 requiring colectomy). There
were also three fetal losses [92].
Using Nationwide Inpatient Sample data,
Kuntz and colleagues were able to calculate
the true incidence of CDI around the time of
labor. They crossed data service records in
obstetrics with diagnoses of CDI between 1998
and 2006. The study sample included 1706
cases. The incidence of CDI in women
hospitalized for childbirth increased from
around 0.4 per 10,000 to 0.6 per 10,000, in
parallel with that of the general population,
which was 40 per 10,000 to 80 per 10,000
during the same period. Most (67%) cases were
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of women who underwent caesarean delivery
[93].
Is CDI really more severe in pregnant
women? Of course, some bias could exist since
severe cases are probably reported more
frequently. Nevertheless, during a large
outbreak that occurred in an obstetric
department, 16 out of 20 women presented
with fever and 9 with leukocytosis. These
percentages of systemic response are not so
common among the general population and
have also been reported in other series [94, 95].
In pregnant women, the Th1 response is
replaced by a Th2 response. Since C.
difficile-induced colitis is characterized by an
influx of neutrophils into the colonic mucosa,
which is mediated by a Th1 immune response,
it has been hypothesized that the
immunoregulation associated with pregnancy
increases the risk of CDI by downregulating the
Th1 response that is necessary to control the
disease [96].
In summary, although the incidence of CDI
in pregnant women has not been specifically
compared with CDI incidence in healthy people
of the same age, they seem to show a substantial
risk of CDI due to their exposure to antibiotics
and the hospital environment (both conditions
occurring in cases of caesarean section
deliveries), and the immune changes associated
to pregnancy. Moreover, CDI in pregnant
women can cause systemic manifestations and
pose the risk of complications for both the
mother and the fetus.
CDI INFECTION IN PEDIATRIC
PATIENTS
CDI has been thoroughly studied in adults, but
not in children, in whom concern about this
infection has risen during the last few years [97].
Currently, CDI is considered a relevant problem
in children, and one which can be occasionally
associated with colectomy, increased length of
hospital stay and mortality [98].
Children under 1 year of age are typically
excluded from being defined as CDI due to the
high rate of asymptomatic carriers, the absence
of toxin A/B receptors in their immature colon,
and the high prevalence of diarrhea due to
other, mainly viral, etiologies [99]. One study
revealed that the isolation of toxigenic C.
difficile strains in feces from children less than
2 years of age has no relationship with the
severity of diarrhea or healing, regardless of
whether or not the patient was treated for C.
difficile [100]. Considering the previous
evidence, the American Academy of Pediatrics
does not recommend microbiological testing in
children less than 1 year of age unless they
present compatible clinical findings and specific
gastrointestinal motility disorders (such as
Hirschsprung’s disease) or in certain
epidemiological contexts (such as outbreaks of
CDI). It is also recommended that children
between 1 and 3 years of age are first screened
for other causes of diarrhea (such as viral
infections) [101]. Whatever the case may be,
early diagnosis is crucial for a favorable
evolution in high-risk groups (especially the
immunocompromised and patients with IBD)
[102].
Common risk factors for CDI in children are
age 1–4 years old, prior antibiotic treatment
(particularly cephalosporins, and penicillins),
and exposure to a hospital environment
[103, 104]. However, antibiotic exposure is not
firmly associated to community-acquired CDI
cases [105]. The relationship between chronic
treatment with PPI and the risk of CDI has been
shown in most, but not all, studies
[104, 106, 107]. Children with inflammatory
bowel disease (IBD) also have a higher risk of
CDI and asymptomatic C. difficile colonization
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[103]. In addition, children that receive solid
organ transplantation and hematopoietic stem
cell transplantation have a higher risk of CDI
[97, 104]. The placement of gastrointestinal
feeding devices has been related to
community-associated CDI in children [105].
As in other patients, the diagnosis of CDI in
children is based on compatible clinical
findings and detection of C. difficile in feces by
microbiological techniques (enzyme
immunoassay, polymerase chain reaction,
microbial culture, etc.) if no other etiologies
are present [99].
Severe complications of CDI, especially
fulminant CDI and pseudomembranous colitis,
are not commonly observed in children. The
clinical presentation of CDI in these patients
consists in most cases of mild to moderate
diarrhea [101, 102, 108, 109]. To improve
patient treatment, several authors have
recommended specific severity criteria for
children [110, 111]. In our opinion, the
criteria defined by Kim et al. are the most
appropriate because they take into account that
severity in pediatric CDI is frequently
overestimated using adult criteria [111]. They
considered that a CDI episode is severe if there
are one or more complications: e.g., ICU
admission, toxic megacolon,
pseudomembranous colitis, intestinal
perforation or surgery, or two or more
laboratory/clinical indicators, such as fever,
hematochezia, elevated white blood cell count,
low albumin, or high creatinine. Fortunately,
the hypervirulent strain (027) has only been
detected infrequently in pediatric patients
[99, 111].
Regarding the treatment of CDI in children,
guidelines recommend, as a first step and
wherever possible, discontinuation of the
antibiotic that triggered the CDI. With respect
to treatment, oral metronidazole is
recommended for children with moderate CDI
and the first recurrence, and oral vancomycin
(with or without intravenous metronidazole)
for severe CDI and a second recurrence [101].
Although there are few studies on the subject,
fecal microbiota transplantation has been
shown to be effective in children with
recurrent CDI [106]. As in adults,
microbiological analysis at the end of
treatment is inadvisable because many patients
continue to present positive toxin
determinations [101].
Recurrent episodes are somewhat more
frequent in adults than in children [99].
Relevant risk factors for recurrence in children
are malignancy, recent surgery, number of
antibiotic exposition by class and IBD
[107, 112].
The increasing incidence of CDI in
hospitalized children [97], difficulties in
diagnostic test interpretation due to high rates
of asymptomatic carriers [102], and high risk of
CDI in specific subgroups (IBD, solid organ and
hematopoietic stem cell transplantation, etc.)
[97, 103, 104, 112] substantiate the requirement
for enhanced investigation into more
appropriate diagnostic algorithms and new
treatments that take into account the special
features of the intestinal microbiome in
children [99].
CONCLUSION
Clostridium difficile infection is a health problem
of great relevance. Knowledge of the
particularities of CDI in different populations
may be relevant in order to better assess the risk
of this disease and establish suitable prevention
measures.
The diagnosis of CDI in patients with
diseases that are complicated by diarrhea, such
as IBD or hematopoietic transplant recipients,
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represents a clinical challenge. Other conditions
(pregnant women, SOT and CRF patients)
deserve a special watchfulness for a higher risk
of complications.
Finally, many aspects of the relevance,
impact, pathogenesis and management of CDI
in the special populations addressed in this
review remain to be elucidated and should be
the subject of future studies.
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